CIK 0001672619 · Non-accelerated filer
Enliven Therapeutics, Inc.
Sign in to watch- Ticker
- ELVN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 811523849
- Phone
- 650-547-5814
- Business address
- 205 PARK ROAD, BURLINGAME, CA, 94010
- Former names
- IMARA Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $2,230,845
- in 7 filings, $1.6M under 10b5-1 plans
Net −$2,230,845. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 37 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-10-08 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −13,167 | $27.95 | $368K | 1,020,626 |
| 2024-10-08 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −100 | $28.51 | $3K | 1,020,526 |
| 2024-10-08 | Ballal Rahul D. Director | Option exercise 10b5-1 | +6,314 | $19.68 | $124K | 28,655 |
| 2024-10-08 | Ballal Rahul D. Director | Option exercise 10b5-1 | +4,106 | $5.52 | $23K | 32,761 |
| 2024-10-08 | Ballal Rahul D. Director | Sale 10b5-1 | −10,420 | $28.17 | $294K | 22,341 |
| 2024-10-08 | Ballal Rahul D. Director | Option exercise · Stock Option (right to buy) 10b5-1 | −6,314 | 69,428 | ||
| 2024-10-08 | Ballal Rahul D. Director | Option exercise · Stock Option (right to buy) 10b5-1 | −4,106 | 12,322 | ||
| 2024-10-07 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −2,707 | $27.61 | $75K | 1,067,180 |
| 2024-10-07 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −2,730 | $27.50 | $75K | 1,033,793 |
| 2024-10-07 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +1,270 | $2.48 | $3K | 2,000 |
| 2024-10-07 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −1,270 | $27.51 | $35K | 0 |
| 2024-10-07 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −1,270 | 180,870 | ||
| 2024-10-04 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −7,522 | $27.51 | $207K | 1,069,887 |
| 2024-10-04 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −12,206 | $27.51 | $336K | 1,036,523 |
| 2024-10-04 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise 10b5-1 | +10,218 | $2.48 | $25K | 10,218 |
| 2024-10-04 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −10,218 | $27.51 | $281K | 0 |
| 2024-10-04 | Hohl Benjamin CHIEF FINANCIAL OFFICER | Option exercise · Stock Option (right to buy) 10b5-1 | −10,218 | 182,140 | ||
| 2024-10-04 | Heyman Richard A. Director | Sale 10b5-1 | −2,825 | $27.51 | $78K | 125,760 |
| 2024-10-01 | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER | Sale 10b5-1 | −527 | $27.54 | $15K | 1,077,409 |
| 2024-10-01 | Kintz Samuel PRESIDENT AND CEO | Sale 10b5-1 | −526 | $27.54 | $14K | 1,048,729 |
Page 16 of 37 · 724 trades